Connect Biopharma Holdings (CNTB) Assets Average (2021 - 2026)
Connect Biopharma Holdings (CNTB) posted Assets Average of $58.1 million for Q1 2026, down 5.91% sequentially from $61.7 million in Q4 2025, and down 40.12% YoY from $97.0 million in Q1 2025.
Connect Biopharma Holdings (CNTB) Assets Average (2021 - 2026) Analysis & Trends
Connect Biopharma Holdings has reported Assets Average for 5 years, with the latest figure at $58.1 million in Q1 2026.
- Quarterly Assets Average fell 40.12% year-over-year to $58.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $58.1 million (down 40.12% YoY) and the FY2025 annual result came in at $78.7 million, down 31.18% from the prior year.
- Assets Average slipped to $58.1 million in Q1 2026 per CNTB's latest filing, from $61.7 million in the prior quarter.
- Over five years, Assets Average peaked at $262.5 million in Q2 2022 and troughed at $58.1 million in Q1 2026.
- A 4-year average of $126.4 million and a median of $97.0 million in 2025 frame the typical range for Assets Average.
- The sharpest annual moves came in 2022 and 2026: Assets Average dropped 10.76% in 2022, then slumped 40.12% in 2026.
- Over 4 years, Assets Average stood at $202.5 million in 2022, then tumbled by 32.99% to $135.7 million in 2023, then plunged by 54.53% to $61.7 million in 2025, then dropped by 5.91% to $58.1 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $58.1 million, $61.7 million, and $75.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Connect Biopharma Holdings | 144.32 Mn | 144.32 Mn | - | 51.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 51.77 Mn |
| Mar 31, 2026 | 58.07 Mn |
| Dec 31, 2025 | 61.72 Mn |
| Sep 30, 2025 | 75.04 Mn |
| Jun 30, 2025 | 87.70 Mn |
| Mar 31, 2025 | 96.98 Mn |
| Dec 31, 2023 | 135.73 Mn |
| Jun 30, 2023 | 157.24 Mn |
| Dec 31, 2022 | 202.55 Mn |
| Jun 30, 2022 | 262.47 Mn |
| Dec 31, 2021 | 226.97 Mn |